survodutide top-line results MASH fibrosis survodutide top-line results MASH fibrosis Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Geographic Atrophy treatment to move to Phase II Geographic Atrophy treatment to move to Phase II Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results